Petros Pharmaceuticals Stock Revenue
| PTPIDelisted Stock | USD 0.03 0 13.35% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Petros Pharmaceuticals' long-term financial health and intrinsic value.
Petros |
Petros Pharmaceuticals Company Revenue Analysis
Petros Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Petros Pharmaceuticals Revenue | 5.11 M |
Most of Petros Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Petros Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Petros Pharmaceuticals reported 5.11 M of revenue. This is 99.93% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 99.95% higher than that of the company.
Petros Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Petros Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Petros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Petros Pharmaceuticals by comparing valuation metrics of similar companies.Petros Pharmaceuticals is currently under evaluation in revenue category among its peers.
Petros Fundamentals
| Return On Equity | -5.71 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (2.80) % | ||||
| Operating Margin | (2.41) % | ||||
| Current Valuation | (1.42 M) | ||||
| Shares Outstanding | 2.14 M | ||||
| Shares Owned By Insiders | 7.39 % | ||||
| Shares Owned By Institutions | 6.79 % | ||||
| Number Of Shares Shorted | 12.35 M | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 0.05 X | ||||
| Revenue | 5.11 M | ||||
| Gross Profit | 3.9 M | ||||
| EBITDA | (10.81 M) | ||||
| Net Income | (14.32 M) | ||||
| Cash And Equivalents | 13.3 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 7.39 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 3.10 X | ||||
| Book Value Per Share | (17.73) X | ||||
| Cash Flow From Operations | (2.6 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (63.15) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 2.2 | ||||
| Market Capitalization | 265.45 K | ||||
| Total Asset | 10.64 M | ||||
| Retained Earnings | (113.21 M) | ||||
| Working Capital | (10.73 M) | ||||
| Net Asset | 10.64 M |
About Petros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Petros Pink Sheet
If you are still planning to invest in Petros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Petros Pharmaceuticals' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |